Balstilimab is under clinical development by Agenus and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase II drugs for Ovarian Cancer have a 26% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Balstilimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AGEN-2034 (balstilimab) is under development for the treatment of metastatic angiosarcoma, metastatic soft tissue sarcomas, metastatic or locally advanced solid tumors including cervical cancer, glioblastoma multiforme, ovarian cancer, advanced cutaneous squamous cell carcinoma, oropharyngeal cancer and non-small cell lung carcinoma, metastatic colorectal cancer and pancreatic cancer. The therapeutic candidate is administered intravenously. The drug candidate is checkpoint modulator antibody acts by antagonizing the programmed death-1 (PD-1, CD279). It is profiled based on retrocyte display technology and secant yeast display platform.
Agenus is a clinical-stage immuno-oncology company that discovers, develops, and commercializes immunotherapeutics for the treatment of various types of cancers and infectious diseases. The company’s pipeline portfolio encompasses vaccines for glioblastoma, genital herpes, and multiple cancer types; vaccine adjuvants for the treatment of shingles and malaria; and checkpoint antibodies targeted at various diseases. The company’s technology portfolio includes antibody discovery platform, vaccine platforms and Heat Shock Protein (HSP) platform. The company collaborates with several pharmaceutical companies such as GSK, Incyte, and Merck. It operates in the US and Europe. Agenus is headquartered in Lexington, Massachusetts, the US.
For a complete picture of Balstilimab’s drug-specific PTSR and LoA scores, buy the report here.